US regulator approves pill form of Wegovy weight-loss drug
PositiveHealth
- The US regulator has approved Wegovy in pill form, marking a significant shift in the weight-loss drug market by providing a non-injection option for patients. This approval represents a milestone for Novo Nordisk, as Wegovy becomes the first GLP-1 medication available in oral form for weight management.
- This development is crucial for Novo Nordisk, as it expands the accessibility of Wegovy, potentially increasing its market share and addressing the growing demand for weight-loss solutions that are easier to administer.
- However, the company faces challenges as recent trials of semaglutide, the active ingredient in Wegovy, have failed to show cognitive benefits for Alzheimer's patients, raising concerns about the drug's broader efficacy and impacting investor confidence amid fluctuating stock performance.
— via World Pulse Now AI Editorial System
